Key Metrics
15.9
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 0.001
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
10 - 15
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.95
5-Year SI
5-year SI
- 0.96 2-year SI
- 0.94 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Pharmacology, Toxicology and Pharmaceutics (all)
SJR
- Q1 Pharmacology, Toxicology and Pharmaceutics (all)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
2.59
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
29%
4 to 6 months
68%
7 to 9 months
3%
Above 9 months
1%
Did you find this useful?
Thank you for your feedback.
Topics Covered
- Hepatocellular carcinoma
- Metabolism
- Psoriasis
- Immunotherapy
- Drug delivery
- Tumor progression
- Lung cancer
- Bioavailability
- Antimicrobial peptides
- Cell entry
- Cardiac ischemia
- Mass spectrometry
- Polyethylene glycol
- Extracellular vesicles
- Triptolide
- Clinical efficacy
- Oxidative stress
- Intestinal permeability
- Tumor microenvironment
- Carcinogenesis
Journal Specifications
| Overview | |
| Publisher | INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES |
| Language | English |
| Frequency | Bi-monthly |
| Publication Time | 19 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Insititute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association |
| Frequency | Bi-monthly |
| Publication Start Year | 2011 |
| Website URL | Visit website |
| Publication Details | |
| Other charges | Visit website |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 19 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
Planning to publish in Acta Pharmaceutica Sinica B ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
N6-Methyladenosine modification of circDcbld2 in Kupffer cells promotes hepatic fibrosis via targeting miR-144-3p/Et-1 axis
- 1 Nov 24
- Acta Pharmaceutica Sinica B
-
Full paper
Respiratory delivered vaccines: Current status and perspectives in rational formulation design
- 1 Nov 24
- Acta Pharmaceutica Sinica B
-
Full paper
Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer
- 1 Nov 24
- Acta Pharmaceutica Sinica B
-
Full paper
Tumor-intrinsic PRMT5 upregulates FGL1 via methylating TCF12 to inhibit CD8+ T-cell-mediated antitumor immunity in liver cancer
- 1 Nov 24
- Acta Pharmaceutica Sinica B
-
Full paper
Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin αvβ3-positive tumors: a first-in-human study
- 1 Nov 24
- Acta Pharmaceutica Sinica B
-
Full paper
Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment
- 1 Nov 24
- Acta Pharmaceutica Sinica B
Scite analysis
Powered by scite_
2.3k articles received 51.9k citations see all
- 882 Supporting
- 50,484 Mentioning
- 52 Contrasting
Editorial notices
- 2 Retractions
- 4 Withdrawals
- 0 Corrections
- 37 Errata
- 0 Expression of Concern
FAQs
How long has Acta Pharmaceutica Sinica B been actively publishing?
Acta Pharmaceutica Sinica B has been in operation since 2011 till date.
What is the publishing frequency of Acta Pharmaceutica Sinica B ?
Acta Pharmaceutica Sinica B published with a Bi-monthly frequency.
How many articles did Acta Pharmaceutica Sinica B publish last years ?
In 2023, Acta Pharmaceutica Sinica B published 454 articles.
What is the eISSN & pISSN for Acta Pharmaceutica Sinica B ?
For Acta Pharmaceutica Sinica B,eISSN is 2211-3843 and pISSN is2211-3835.
What is Citescore for Acta Pharmaceutica Sinica B ?
Citescore for Acta Pharmaceutica Sinica B is 15.9.
What is SNIP score for Acta Pharmaceutica Sinica B ?
SNIP score for Acta Pharmaceutica Sinica B is 2.59.
What is the SJR for Acta Pharmaceutica Sinica B ?
SJR for Acta Pharmaceutica Sinica B is Q1.
Who is the publisher of Acta Pharmaceutica Sinica B ?
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES is the publisher of Acta Pharmaceutica Sinica B.